Intuitive Surgical (ISRG) Tops Q3 EPS by 101c
Get Alerts ISRG Hot Sheet
Price: $399.09 -0.25%
EPS Growth %: +15.4%
Financial Fact:
Gross profit: 487M
Today's EPS Names:
FSI, RELV, NEOM, More
EPS Growth %: +15.4%
Financial Fact:
Gross profit: 487M
Today's EPS Names:
FSI, RELV, NEOM, More
Join SI Premium – FREE
Intuitive Surgical (NASDAQ: ISRG) reported Q3 EPS of $5.24, $1.01 better than the analyst estimate of $4.23. Revenue for the quarter came in at $590 million versus the consensus estimate of $580.37 million.
- Worldwide da Vinci procedures grew approximately 15% over the third quarter of 2014, driven primarily by growth in U.S. general surgery procedures and broad-based procedure growth in Asia and other international markets.
- The Company shipped 117 da Vinci Surgical Systems, compared with 111 in the third quarter of 2014 and 118 in the second quarter of 2015.
- Non-GAAP* revenue of $590 million for the quarter grew approximately 10% compared with $534 million for the third quarter of 2014.
- Third quarter 2015 non-GAAP* net income was $199 million, or $5.24 per diluted share, compared with $145 million, or $3.92 per diluted share, for the third quarter of 2014. The Company's third quarter 2015 income tax expense benefited by approximately $29 million, or $0.77 per diluted share, relating to certain tax benefits recorded in the quarter.
- During the third quarter 2015 the Company filed for FDA 510(k) clearances in the U.S. for Single-Site instruments and 30mm EndoWrist stapler products for the da Vinci XiSurgical System.
For earnings history and earnings-related data on Intuitive Surgical (ISRG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 2 reasons why Tesla stock fell on Thursday
- Pulse Biosciences, Inc. (PLSE) Tops Q4 EPS by 2c
- Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
Create E-mail Alert Related Categories
Earnings, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!